ABOS Acumen Pharmaceuticals
- 3.400
- +0.040+1.19%
Acumen Pharmaceuticals News
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study
Acumen Pharmaceuticals (ABOS) said Wednesday that it has dosed the first patient in the phase 2 study of sabirnetug for patients of early Alzheimer's disease. The phase 2 trial is currently enrolling
Acumen Pharmaceuticals Says First Patient Dosed In ALTITUDE-AD, A Phase 2 Clinical Trial Of Sabirnetug In Early Alzheimer's Disease
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzh
Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic solub
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets
Daily rights tracking | Over 50% increase in two days! Earn 2x bonus on GameStop with multiple calls in a single pass
Apple's earnings surged more than 6% after that. This Friday, bullish options with an exercise price of 190 US dollars were active, reaching 126,600; Palantir's pre-performance options trading volume surged, and multiple call orders received capital.
Watching Eledon Pharmaceuticals, Acumen Pharmaceuticals; Shares See Volume On TipRanks Article Titled "These 2 'Strong Buy' Penny Stocks Are Poised for Over 300% Gains, Say Analysts"
Watching Eledon Pharmaceuticals, Acumen Pharmaceuticals; Shares See Volume On TipRanks Article Titled "These 2 'Strong Buy' Penny Stocks Are Poised for Over 300% Gains, Say Analysts"
Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany o
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
Lonza Enters Manufacturing Agreement for Acumen's Alzheimer's Disease Drug Candidate
Lonza Group (LONN.SW) and Acumen Pharmaceuticals signed a clinical development and commercialization deal for the latter's sabirnetug drug candidate, which is being studied for the treatment of Alzhei
Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved
Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
Acumen Pharmaceuticals Files for $200M Mixed Shelf Offering
Acumen Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Acumen Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals with a Buy and maintains $15 price target.
Acumen Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 301.07% HC Wainwright & Co. $15 → $15 Maintains Buy 12/12/2023 113.9% Deutsche Bank → $8 Initia
Buy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer's Treatment Development and Attractive Valuation
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q4 2023 Earnings Conference
The following is a summary of the Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript:Financial Performance:Acumen Pharmaceuticals ended 2023 with cash and marketable securities worth
Analysis
Price Target
No Data
